| 1. |
- Protudjer, Jennifer, et al.
(författare)
-
Puberty and asthma in a cohort of Swedish children
- 2014
-
Ingår i: Annals of Allergy, Asthma & Immunology. - Stockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics. - 1534-4436 .- 1081-1206.
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Abrams, EM, et al.
(författare)
-
The need for patient voices in food allergy research
- 2020
-
Ingår i: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. - : Elsevier BV. - 1534-4436. ; 125:3, s. 346-347
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
- Ahlbeck, Lars, 1964-, et al.
(författare)
-
Intralymphatic allergen immunotherapy against pollen allergy. A 3-year open follow-up study of 10 patients
- 2018
-
Ingår i: Annals of Allergy, Asthma & Immunology. - : Elsevier. - 1081-1206 .- 1534-4436. ; 121:5, s. 626-627
-
Tidskriftsartikel (refereegranskat)abstract
- To date, allergen immunotherapy (AIT) is the only treatment that affects the long-term development of allergic rhinoconjunctivitis and induces clinical tolerance primarily by stimulating regulatory T (Treg) cells, attenuating T helper 2 (Th2) responses and synthesis of blocking antibodies1. Conventional AIT with subcutaneous injections, sublingual tablets or drops is effective, but consumes time and resources 2.
|
|
| 6. |
|
|
| 7. |
- Andersson, F, et al.
(författare)
-
Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice
- 2001
-
Ingår i: Annals of Allergy, Asthma & Immunology. - 1081-1206 .- 1534-4436. ; 86:5, s. 537-544
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Budesonide and sodium cromoglycate are both recommended as maintenance therapy for childhood asthma. Objective: To compare the cost-effectiveness of these two treatment strategies in clinical practice, in an open-label, pharmacoeconomic clinical trial. Methods: Health economics were evaluated in 138 children. ages 5 to 11 years, with unstable asthma not previously treated with corticosteroids or cromones. The asthma was stabilized during 4 to 6 weeks with budesonide 200 to 400 mug twice daily. The children were then randomly allocated to one of the two treatment strategies aiming at maintaining asthma control for 12 months, budesonide 400 mug/day (N = 69) or sodium cromoglycate 60 mg/day (N = 69). If asthma control was judged unsatisfactory, the doses were increased or the children were switched to the alternate treatment. Results: In children continuing on the same treatment, the degree of asthma control was similar in the two groups at study end. To maintain asthma control, 42% of cromoglycate children switched to budesonide, and then experienced a 14% increase in symptom-free days. No budesonide patient had to switch therapy because of lack of asthma control. Although not statistically significant, total annual cost per patient was 24% (Swedish kronor 4195, US $487, Euro 485) lower in the budesonide than the cromoglycate group, mainly due to a lower cost for asthma medication. Conclusions: A budesonide strategy for continued maintenance treatment, after an initial period of stabilizing treatment with budesonide, resulted in lower costs and less drug switches than did a strategy with sodium cromoglycate.
|
|
| 8. |
|
|
| 9. |
- Blumenschein, Karen, et al.
(författare)
-
Relationship Between Quality of Life Instruments, Health State Utilities, and Willingness to Pay in Patients with Asthma
- 1998
-
Ingår i: Annals of allergy, asthma, & immunology. - : Elsevier Inc. - 1534-4436 .- 1081-1206. ; 80:2, s. 189-194
-
Tidskriftsartikel (refereegranskat)abstract
- In asthma, a substantial impact of disease is on quality of life rather than survival. To date, the quality of life effects of asthma have not been quantitated. The purpose of this study was to quantitate the quality of life effects of asthma via measurement of the health utility of asthmatic patients, and the willingness to pay for an asthma cure. A second goal was to analyze how these measures are related to the different dimensions of quality of life as measured by general and disease specific quality of life instruments. Health utilities were measured on a scale between 0 and 1 using the rating scale, time trade off, and standard gamble methods. Willingness to pay was elicited using both the dichotomous choice and the bidding game approach. Quality of life was assessed using both a generic instrument (the SF-36) and a disease-specific instrument (the Asthma TyPE). Sixty-nine patients with asthma were surveyed. The mean health utility was 0.68 with the rating scale method, 0.89 with the time trade off, and 0.91 with the standard gamble. On average, patients were willing to pay between $200 to $350 dollars more per month for an asthma cure. Nearly all correlations between dimensions of quality of life, health state utilities, and willingness to pay were in the expected direction. The two quality of life instruments performed about equally well in terms of being correlated with and being able to explain the responses to the health state utility questions and the willingness to pay questions. Correlations between the dimensions of the Asthma TyPE and the SF-36 were also fairly high. Further work should focus on validating and refining the different methods of quantitating quality of life for asthma patients.
|
|
| 10. |
|
|
